Quick Answer
BioNexus Gene Lab Corp reported Stockholders Equity of $8.32 million for the year ending 2024.
- BioNexus Gene Lab Corp showed a decrease of -13.8% in Stockholders Equity from 2023 to 2024.
- This data is from BioNexus Gene Lab Corp's annual report (Form 10-K), filed with the SEC on April 15, 2025.
- XBRL data for this metric is available from 2017 to 2024 (8 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q1 2019: $1.48 million | Q2 2019: $1.39 million | Q3 2019: $1.26 million | Q1 2020: $6.19 million | Q2 2020: $6.20 million | Q3 2020: $6.68 million | Q1 2021: $6.79 million | Q2 2021: $6.81 million | Q3 2021: $7.05 million | Q1 2022: $7.13 million | Q2 2022: $6.82 million | Q3 2022: $6.42 million | Q1 2023: $6.19 million | Q2 2023: $5.59 million | Q3 2023: $9.32 million | Q4 2023: $9.66 million | Q1 2024: $9.34 million | Q2 2024: $9.55 million | Q3 2024: $9.39 million | Q4 2024: $8.32 million | Q1 2025: $7.77 million | Q2 2025: $7.52 million | Q3 2025: $6.82 million.
- Over the full 8 years of available data (2017 to 2024), BioNexus Gene Lab Corp's Stockholders Equity has grown by 8,695.5%.
- Historical annual values: Fiscal year 2024: $8.32 million | Fiscal year 2023: $9.66 million | Fiscal year 2022: $6.67 million | Fiscal year 2021: $7.18 million | Fiscal year 2020: $6.66 million | Fiscal year 2019: $1.12 million | Fiscal year 2018: $1.52 million | Fiscal year 2017: $94.6 thousand.
- Data sourced from SEC EDGAR public filings as of August 7, 2026.
Last verified: